Revenue
2016
2017
2018
2019
2022
2023
2024
2025
Dianthus Therapeutics, Inc. (DNTH)
Price$107.39Cached quote
Net income
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.0M | $6.2M | $2.8M | $6.4M | — | — | $0 | $0 | $0 | $0 |
| Research & development | $145.6M | $83.1M | $32.8M | $29.4M | $46.8M | $50.6M | $59.2M | $41.3M | $27.9M | $5.8M |
| Operating expenses | $180.0M | $108.1M | $51.0M | $36.1M | $74.7M | $78.7M | $83.0M | $60.0M | $35.7M | $9.3M |
| Operating income | −$177.9M | −$101.9M | −$48.2M | −$29.7M | −$74.7M | −$78.7M | −$83.0M | −$60.0M | −$35.7M | −$9.3M |
| Operating margin | −8,739.34% | −1,633.74% | −1,704.67% | −462.91% | — | — | — | — | — | — |
| EBITDA | −$177.8M | −$101.8M | −$48.1M | −$27.8M | −$72.7M | −$76.7M | −$81.1M | −$59.1M | −$35.4M | −$9.3M |
| EBITDA margin | −8,733.89% | −1,632.21% | −1,702.30% | −432.91% | — | — | — | — | — | — |
| Net income | −$162.3M | −$85.0M | −$43.6M | −$28.5M | −$71.1M | −$74.9M | −$76.8M | −$57.5M | −$35.5M | −$9.4M |
| Net profit margin | −7,973.33% | −1,362.77% | −1,541.22% | −443.76% | — | — | — | — | — | — |
| Basic EPSper basic share | -$4.20 | -$2.55 | -$8.45 | -$32.57 | -$1,424.16 | -$1,887.84 | -$2,285.28 | -$3,455.52 | -$21,108.48 | -$71,925.60 |
| Diluted EPSper diluted share | -$4.20 | -$2.55 | -$8.45 | -$32.57 | -$1,424.16 | -$1,887.84 | -$2,285.28 | -$3,455.52 | -$21,108.48 | -$71,925.60 |
Owners
Reported shareholders
14.96%of listed shares
FMR LLC8.2M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
FMR LLC | 14.96%8.2M shares |
BlackRock, Inc. | 7.53%4.12M shares |
T. Rowe Price Investment Management, Inc. | 7.10%3.89M shares |
WELLINGTON MANAGEMENT GROUP LLP | 5.89%3.23M shares |
Fairmount Funds Management LLC | 4.63%2.54M shares |
PRICE T ROWE ASSOCIATES INC /MD/ | 4.59%2.51M shares |
STATE STREET CORP | 4.30%2.36M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.94%2.16M shares |
Avidity Partners Management LP | 3.84%2.1M shares |
Octagon Capital Advisors LP | 3.36%1.84M shares |
TCG Crossover Management, LLC | 3.06%1.68M shares |
FRED ALGER MANAGEMENT, LLC | 2.38%1.3M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.30%1.26M shares |
Venrock Adviser, LLC | 2.15%1.18M shares |
UBS Group AG | 2.08%1.14M shares |
DEERFIELD MANAGEMENT COMPANY, L.P. | 2.05%1.13M shares |
JENNISON ASSOCIATES LLC | 1.86%1.02M shares |
Polar Capital Holdings Plc | 1.86%1.02M shares |
CITADEL ADVISORS LLC | 1.78%974.91K shares |
FRANKLIN RESOURCES INC | 1.77%968.98K shares |
Percentages use 54.8M shares of this listed class outstanding on Jun 30, 2026.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 17, 2026Form 4 · 10b5-1 | Veness Adam MSVP, General Counsel and Sec. | SellCommon Stock | 13.2K | $81.38 | $1.08M | 0 |
| Jun 17, 2026Form 4 · 10b5-1 | Veness Adam MSVP, General Counsel and Sec. | SellCommon Stock | 16.8K | $80.34 | $1.35M | 13.2K |
| Jun 1, 2026Form 4 · 10b5-1 | Randhawa SimratEVP, Head of R&D | SellCommon Stock | 4.2K | $91.37 | $380.0K | 4.0K |
| Jun 1, 2026Form 4 · 10b5-1 | Randhawa SimratEVP, Head of R&D | SellCommon Stock | 16.9K | $90.72 | $1.54M | 8.2K |
| Jun 1, 2026Form 4 · 10b5-1 | Randhawa SimratEVP, Head of R&D | SellCommon Stock | 5.4K | $89.72 | $487.0K | 25.1K |